HRTX Heron Therapeutics Dashboard

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.

Company profile

Ticker

HRTX

Exchange

NASDAQ

Website

www.herontx.com/

CEO

Barry Quart

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

ADVANCED POLYMER SYSTEMS INC /DE/, AP PHARMA INC /DE/

SEC CIK

0000818033

Corporate docs

Articles of Incorporation & Bylaws

IRS number

942875566

HRTX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Heron Therapeutics Awarded U.S. Patent #10,953,018 'Formed hexagonal boron nitride body, heat-treated hexagonal boron nitride body and processes for producing the same'

23 Mar 21

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=5&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=205&f=G&l=50&co1=AND&d=PTXT&s1=%22*%22&OS=%22*%22&RS=%22*%22

12 Health Care Stocks Moving In Friday's Pre-Market Session

26 Feb 21

Heron Therapeutics Q4 EPS $(0.68) Down From $(0.65) YoY, Net Product Sales $20.60M Down From $35.08M YoY

24 Feb 21

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.68) per share. This is a 4.62 percent decrease over losses of $(0.65) per share from the same period last year. The company reported $20.60 million in

Heron Therapeutics Highlights Publication Of Results From EPOCH 1 Follow-On Study Of HTX-001 In Patients With Undergoing Bunionectomy Surgery: '77% of Bunionectomy Patients Receiving HTX-011 Required No Opioids...'

21 Jan 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in Phunware, Broadwind, Seelos Therapeutics, Golden Nugget Online Gaming, or Heron Therapeutics?

6 Apr 21

NEW YORK, April 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, BWEN, SEEL, GNOG, and HRTX.

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

24 Feb 21

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences

17 Feb 21

SAN DIEGO, Feb. 17, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery

21 Jan 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

24 Feb 21

17 Apr 21

31 Dec 21

Financial summary

Financial statements Chart HRTX financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	105.14M	105.14M	105.14M	105.14M	105.14M	105.14M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	20.43M	19.01M	17.52M	15.4M
Cash used (since last report)	n/a	n/a	72.87M	67.81M	62.48M	54.93M
Cash remaining	n/a	n/a	32.27M	37.32M	42.66M	50.21M
Runway (months of cash)	n/a	n/a	1.6	2.0	2.4	3.3

Beta Read what these cash burn values mean

Recent insider trades

HRTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Apr 21	Christian Waage	Common Stock	Sell	Dispose S	No	Yes	17.5126	300	5.25K	4,100
13 Apr 21	Lisa Peraza	Common Stock	Payment of exercise	Dispose F	No	No	16.66	191	3.18K	11,945
13 Apr 21	Lisa Peraza	Common Stock	Option exercise	Aquire M	No	No	0	552	0	12,136
13 Apr 21	Lisa Peraza	RSU Common Stock	Option exercise	Dispose M	No	No	0	552	0	7,729
13 Apr 21	Manhard Kimberly	Common Stock	Payment of exercise	Dispose F	No	No	16.66	433	7.21K	1,634
13 Apr 21	Manhard Kimberly	Common Stock	Option exercise	Aquire M	No	No	0	1,250	0	2,067
13 Apr 21	Manhard Kimberly	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,250	0	17,500
13 Apr 21	John Poyhonen	Common Stock	Payment of exercise	Dispose F	No	No	16.66	433	7.21K	20,414
13 Apr 21	John Poyhonen	Common Stock	Option exercise	Aquire M	No	No	0	1,250	0	20,847
13 Apr 21	John Poyhonen	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,250	0	17,500

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

HRTX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	183	177	+3.4%
Opened positions	25	20	+25.0%
Closed positions	19	33	-42.4%
Increased positions	52	61	-14.8%
Reduced positions	63	63	–

13F shares	Current	Prev Q	Change
Total value	2.07B	1.33B	+56.3%
Total shares	97.87M	89.47M	+9.4%
Total puts	46.8K	56.4K	-17.0%
Total calls	112.8K	27.8K	+305.8%
Total put/call ratio	0.4	2.0	-79.5%

Largest owners	Shares	Value	Change
BEN Franklin Resources	12.69M	$268.56M	-1.5%
Vanguard	8.31M	$175.92M	+3.9%
Tang Capital Partners	7.64M	$161.61M	NEW
Wellington Management	6.94M	$146.8M	+92.0%
BLK Blackrock	6.89M	$145.76M	+18.2%
Baker Bros. Advisors	5.99M	$126.88M	0.0%
ArrowMark Colorado	5.36M	$113.48M	+6.0%
STT State Street	3.98M	$84.28M	-9.7%
Clearbridge Advisors	3.45M	$73.11M	+0.5%
JPM JPMorgan Chase & Co.	3.1M	$65.63M	+4.1%

Largest transactions	Shares	Bought/sold	Change
Tang Capital Partners	7.64M	+7.64M	NEW
Wellington Management	6.94M	+3.32M	+92.0%
Tang Capital Management	0	-2.9M	EXIT
Consonance Capital Management	0	-2.01M	EXIT
Norges Bank	1.17M	+1.17M	NEW
BLK Blackrock	6.89M	+1.06M	+18.2%
Iron Triangle Partners	865.07K	+865.07K	NEW
Kensico Capital Management	0	-542.1K	EXIT
Citadel Advisors	660.98K	+539.64K	+444.7%
FIL	0	-481.2K	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Factset Research Systems • Durect • Glaxosmithkline • Liquidia • Vanda Pharmaceuticals • Pacira BioSciences • Acelrx Pharmaceuticals • Trevena • Tesaro

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AbCellera, Acacia, add, adult, advocacy, agonist, Albania, amidst, amisulpride, amplify, analgesia, ANJESO, antibody, arbitrage, array, Aspen, attendance, Bamlanivimab, Baudax, Biden, Bio, bridge, Bulgaria, Canadian, carryback, Casirivimab, cell, centralized, charitable, child, CHMP, Cmax, coaching, cocktail, combating, conference, conflict, coordinated, Croatia, Czech, daily, deep, demographic, developmental, disallowed, dissipate, DOJ, Durect, EC, EEA, Eli, Emergency, employed, endeavor, epidemic, epinephrine, Estesevimab, Estonia, Etesevimab, ethnicity, Europe, evidenced, excipient, expeditiously, expertise, female, field, forgiven, gender, Gilead, GLP, heading, higher, home, hotline, Hungary, hybrid, hydrochloride, Iceland, imdevimab, implant, impurity, indentured, induction, infection, Innocoll, internet, job, Junshi, justify, Latvia, leadership, Lilly, Lithuania, longevity, lowest, mAb, Macedonia, male, Mallinckrodt, Malta, Math, mentoring, Monaco, monoclonal, mortality, neutralizing, Norway, occupational, OFIRMEV, organizational, payout, peak, penetration, peptide, Pfizer, Pharmacare, phone, pill, plasma, Poland, PONV, POSIMIR, posing, postsurgical, PPP, protein, purpose, quarantining, race, recombinant, Regeneron, remdesivir, remote, reorganization, reproductive, Republic, respiratory, restaurant, risky, Romania, rulemaking, salary, Secretary, SENSORCAINE, Serbia, Shanghai, simply, slated, Slovakia, Slovenia, somatic, spike, staffed, staffing, survey, syndrome, Takeda, task, taxpayer, tie, tradipitant, trafficking, travel, tuition, Turkey, turnover, underrepresented, unfair, unpredictable, upholding, Vanda, VEKLURY, ventilation, weighting, women, worksite, worldwide, Xaracoll, ZYNRELEF

Removed: Advanced, affiliated, AMCO, APP, APS, Bulletin, concentration, founded, Hospira, OTC, realigned, realignment, receptivity, refocused, refocusing, reincorporated, resold, revalued, scheduled

From filing 10-K 2020 FY